Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Kazia Therapeutics Ltd KZIA

Healthcare Biotechnology
Kazia Therapeutics Limited is an oncology-focused drug development company. The Company operates in the pharmaceutical research and development business. The Company’s lead program is paxalisib, an investigational brain-penetrant inhibitor of the PI3K / Akt / mTOR pathway, which is being developed to treat multiple forms of brain cancer. It is also developing EVT801, a small-molecule inhibitor... see more

Recent & Breaking News (NDAQ:KZIA)

Kazia Licenses Cantrixil, a Clinical-stage, First-in-class Ovarian Cancer Drug Candidate, to Oasmia Pharmacetical AB

PR Newswire March 1, 2021

Global Coalition for Adaptive Research, Kazia, and Kintara Announce Commencement of Kazia's Paxalisib and Kintara's VAL-083 in GBM AGILE Trial

Business Wire January 6, 2021

Kazia to Collaborate with Pacific Pediatric Neuro-Oncology Consortium (PNOC) for New Paxalisib Combination Study in DIPG

PR Newswire December 10, 2020

Top-line Final Data from Cantrixil Phase I Study Confirms Prior Positive Efficacy and Safety Signals

PR Newswire December 9, 2020

Kazia Therapeutics (KZIA): Phase IIa Shows Good Safety, Consistent Efficacy

Accesswire December 3, 2020

Kazia Presents Further Paxalisib Data At Sno, Confirming Earlier Positive Safety And Efficacy Signals In Glioblastoma

PR Newswire November 17, 2020

Kazia Executes Agreement To Commence GBM Agile Pivotal Study

PR Newswire October 16, 2020

Kazia Enters Clinical Collaboration With Dana-farber Cancer Institute For Primary CNS Lymphoma

PR Newswire September 22, 2020

US FDA Starting to Grant Fast-Track Designation for Glioblastoma Treatments

Livemoney September 16, 2020

Edison issues ADR outlook on Kazia Therapeutics (KZIA)

Accesswire September 2, 2020

US FDA Awards Orphan Drug Designation (ODD) To Paxalisib For Malignant Glioma, Including DIPG

PR Newswire August 23, 2020

US FDA Awards Fast Track Designation (FTD) to Paxalisib for Glioblastoma

PR Newswire August 19, 2020

US FDA Grants Rare Pediatric Disease Designation (RPDD) to Paxalisib for DIPG

PR Newswire August 6, 2020

Kazia Presents Further Paxalisib and Cantrixil Data at AACR, Reinforcing Positive Efficacy Signals for both Drugs

PR Newswire June 22, 2020

Kazia Presents Interim Paxalisib Phase II Data at ASCO Showing Positive Overall Survival Signal

PR Newswire May 31, 2020

Kazia's Paxalisib Shows Positive Overall Survival Signal in Phase II Glioblastoma Study

PR Newswire April 7, 2020

Edison issues ADR update on Kazia Therapeutics (KZIA)

Accesswire January 13, 2020

Kazia Initiates Preparatory Activities to Bring GDC-0084 into GBM AGILE, an International Phase II / III Study in Glioblastoma

PR Newswire December 10, 2019

Edison issues ADR outlook on Kazia Therapeutics (KZIA)

Accesswire December 2, 2019

Positive Interim Efficacy Data from GDC-0084 Phase II Study in Glioblastoma Released at SNO Conference

PR Newswire November 24, 2019